Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inmune Bio (INMB) Income from Continuing Operations (2018 - 2025)

Inmune Bio's Income from Continuing Operations history spans 8 years, with the latest figure at 7433000.0 for Q3 2025.

  • For Q3 2025, Income from Continuing Operations rose 39.5% year-over-year to 7433000.0; the TTM value through Sep 2025 reached 51376000.0, down 23.66%, while the annual FY2024 figure was 42635000.0, 42.08% down from the prior year.
  • Income from Continuing Operations for Q3 2025 was 7433000.0 at Inmune Bio, up from 24571000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 4548000.0 in Q1 2021 and bottomed at 24571000.0 in Q2 2025.
  • The 5-year median for Income from Continuing Operations is 8379000.0 (2023), against an average of 8915210.53.
  • The largest annual shift saw Income from Continuing Operations crashed 211.06% in 2021 before it surged 39.5% in 2025.
  • A 5-year view of Income from Continuing Operations shows it stood at 9030000.0 in 2021, then surged by 37.52% to 5642000.0 in 2022, then tumbled by 48.51% to 8379000.0 in 2023, then decreased by 12.98% to 9467000.0 in 2024, then grew by 21.49% to 7433000.0 in 2025.
  • Per Business Quant, the three most recent readings for INMB's Income from Continuing Operations are 7433000.0 (Q3 2025), 24571000.0 (Q2 2025), and 9905000.0 (Q1 2025).